Hennion & Walsh Asset Management Inc. Has $3.06 Million Stock Holdings in Kura Oncology, Inc. $KURA

Hennion & Walsh Asset Management Inc. boosted its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 37.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 294,805 shares of the company’s stock after purchasing an additional 79,955 shares during the quarter. Hennion & Walsh Asset Management Inc. owned about 0.34% of Kura Oncology worth $3,063,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. EcoR1 Capital LLC lifted its stake in shares of Kura Oncology by 59.1% during the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after buying an additional 1,559,702 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after buying an additional 1,121,228 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after buying an additional 738,761 shares during the last quarter. Sector Gamma AS bought a new position in Kura Oncology in the 3rd quarter valued at about $3,880,000. Finally, UBS Group AG raised its holdings in Kura Oncology by 332.5% in the 3rd quarter. UBS Group AG now owns 485,570 shares of the company’s stock valued at $4,297,000 after acquiring an additional 373,287 shares during the period.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $8.13 on Wednesday. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $718.12 million, a price-to-earnings ratio of -2.56 and a beta of 0.22. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $12.49. The company has a 50-day simple moving average of $8.41 and a two-hundred day simple moving average of $9.49.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%.The business had revenue of $17.34 million for the quarter, compared to analyst estimates of $34.71 million. Analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Buying and Selling

In other Kura Oncology news, insider Mollie Leoni sold 8,180 shares of Kura Oncology stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the transaction, the insider directly owned 267,274 shares of the company’s stock, valued at $2,261,138.04. The trade was a 2.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Teresa Brophy Bair sold 11,208 shares of Kura Oncology stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the transaction, the insider directly owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This represents a 4.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 36,068 shares of company stock valued at $305,135. 6.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Tuesday, January 13th. Wedbush decreased their target price on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. Wall Street Zen lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Mizuho dropped their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.86.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.